Iran ultimatum EXTENDED to Apr 6. Mar 27 deadline passed — no military action. • Oil risk premium may ease • KOSPI exporters get room • Uncertainty delayed, not resolved Watch USD/KRW and crude. Not financial advice. #FutureLog #KOREA #KOSPI #Geopolitics

ELCC 2026 Day 3: ADC combos dominating Barcelona. Alteogen locked $579M from Biogen — 2nd Q1 tech-out. Every ADC readout expands ALT-B4's TAM. The platform enables the drugs winning. Not a recommendation. #FutureLog #KOREA #KOSDAQ #KBio #ELCC2026 $196170

Gemvax consecutive limit-down Day 2. GV1001 Alzheimer's Phase 2 failed. Stock -50%+ in 48hrs. Alzheimer's Phase 2 success: ~25%. Single-pipeline = binary risk. Platform vs pipeline matters. DYOR. #FutureLog #KOREA #KOSDAQ #KBio $082270

BTS ARIRANG expected Billboard 200 #1. 5M+ copies shipped. Revenue stack reactivated: albums > merch > tour > streaming. HYBE world tour = Q2 catalyst. K-Wave is structural. Each comeback multiplies the flywheel. DYOR. #FutureLog #KOREA #KOSPI #BTS #KWave $352820

Samsung AGM: HBM4E roadmap reaffirmed. Mass production 2027. Lost ground on HBM3E to SK hynix. HBM4 = leapfrog attempt. Real competition: packaging yield. Korea = 95% global HBM. DYOR. #FutureLog #KOREA #KOSPI #HBM $005930

AI compute needs what Korea dominates: 1. Ultra-HV transformers — HD Hyundai Electric 2. HBM memory — Samsung + SK hynix (95%) 3. Precision cooling — Daesung Industrial Demand structural through 2031+. DYOR. #FutureLog #KOREA #KOSPI #AIInfrastructure

Friday KOSPI wrap: Iran deadline > Apr 6 — risk delayed. Sector divergence: • Bio: Alteogen deal vs Gemvax collapse • K-Wave: BTS + APR global push • AI Infra: Samsung HBM4E, grid orders Not financial advice. #FutureLog #KOREA #KOSPI #KOSDAQ

Q1 K-Wave scorecard: BTS ARIRANG: 5M+ copies, Billboard #1 expected APR: Sephora Europe expansion Samyang: Record revenue globally 3 sectors, 1 thesis: Korean cultural IP monetizes at scale. Not a recommendation. #FutureLog #KOREA #KOSPI #KWave

This week in K-Bio: + Alteogen: $579M Biogen deal (2nd Q1 tech-out) + ELCC: ADC data reinforcing platform thesis - Gemvax: GV1001 failed, -50% in 2 days Platform biotechs compound. Pipeline = coin flip. DYOR. #FutureLog #KOREA #KOSDAQ #KBio

Samsung HBM4E qualification firming up. Korea's AI infra stack: • HBM: Samsung + SK hynix (95% global share) • Grid: HD Hyundai Electric, Hyosung Heavy • Cooling: Daesung Industrial Structural demand through 2031+. DYOR. #FutureLog #KOREA #KOSPI #AIInfrastructure $005930

ELCC 2026 Barcelona wrap: ADC combos showed strong data across solid tumors. SC delivery = next frontier. Alteogen: 2 tech-outs in Q1 ($579M Biogen + 1). ALT-B4 positioned for ADC era. Platform > pipeline. DYOR. #FutureLog #KOREA #KOSDAQ #KBio #ELCC2026 $196170

BTS ARIRANG Billboard 200 results drop tomorrow. 5M+ copies. Physical dominance. Global streaming surge. If #1: HYBE flywheel validated again. Tour revenue H2 catalyst. Korean cultural IP = investable at scale. DYOR. #FutureLog #KOREA #KOSPI #BTS #KPOP $352820

KOSPI held 2,580 despite Iran tension (Apr 6 deadline). Foreign net buyers 3 straight days. Week ahead: • BTS Billboard 200 chart Sunday • Samsung HBM4E updates • Korea March CPI (Apr 1) Not financial advice. #FutureLog #KOREA #KOSPI #WeekAhead

US transformer backlog extends to 2028+. Every AI data center needs grid infra BEFORE it runs. HD Hyundai Electric + Hyosung Heavy filling the gap. Grid = picks-and-shovels of AI. Personal research, not advice. #FutureLog #KOREA #KOSPI #AIInfrastructure $267260

Korea week ahead: 1. Iran deadline now Apr 6 2. ELCC data digestion — ADC winners emerge 3. Samsung HBM4E follow-through 4. BTS Billboard chart Sunday 5. KOSPI options expiry + foreign flows Not a recommendation. #FutureLog #KOREA #KOSPI #KoreaStocks

BTS ARIRANG on track for Billboard 200 #1. 5M+ copies shipped. Revenue stack: album > merch > tour > streaming. HYBE world tour = H2 concert revenue. Multi-artist model: BTS is catalyst, not ceiling. DYOR. #FutureLog #KOREA #KOSPI #BTS #KPOP $352820

ELCC 2026 wrapping up. ADC combos dominated Barcelona. Alteogen ALT-B4 enables SC delivery for next-gen biologics. 2 tech-out deals Q1 ($579M Biogen +1). Platform thesis compounding. DYOR. #FutureLog #KOREA #KOSDAQ #KBio #ELCC2026 $196170

한번 가봐야겠군요 #KFOOD #FutureLog #KOSPI

ELCC 2026 코펜하겐 1일차 진행 중. SC(피하주사) 전환이 핵심 화두. 알테오젠 ALT-B4 플랫폼이 정확히 이 영역. 키트루다 SC 데이터, ADC 병용, 바이오마커 발표 금요일까지 계속. 각 긍정적 데이터 = 한국 히알루로니다제 투자 논리 강화. 투자 권유가 아닌 개인적 분석입니다. #FutureLog #KOREA #KOSDAQ #KBio #ELCC2026 $196170

이란-미국 긴장에도 KOSPI +2-3% 반등 중. 외국인 4거래일 연속 순매수. 원/달러 환율 안정세. 유가 하락이 한국 수입 물가에 긍정적. 이번 주 핵심: ELCC 바이오 촉매(내일), AI 인프라 수주 사이클 지속. 개인적인 리서치이며 투자 추천이 아닙니다. #FutureLog #KOREA #KOSPI